Title : Imaging PARP with [18F]rucaparib in pancreatic cancer models.

Pub. Date : 2022 May 26

PMID : 35614267






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. rucaparib BRCA1 DNA repair associated Homo sapiens